Furiex Pharmaceuticals Inc., of Morrisville, N.C., and Menarini Group, of Florence, Italy, said they entered a license deal giving Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East, while Furiex will retain full development and commercialization rights in the U.S., Japan and Canada

Takeda and Affymax share marketing rights in the U.S., where the drug is under review. (See BioWorld Today, June 28, 2006

In 2004, the company acquired the sales, marketing and distribution rights in the U.S

The HibTiter vaccine is a previously marketed pediatric vaccine using glycoconjugate technology for which Nuron acquired rights in the U.S., Japan and other markets from Wyeth LLC

January | February | March | April | May | June | July | August | September | October | November | December | December - 2012 Company Company Type/Product Area Terms/Details Amarantus BioScience Inc. Power3 Medical Products Inc. Deal to buy all of the intellectual property assets from Power3, giving Amarantus the ability to acquire IP for the diagnosis of multiple neurodegenerative diseases and oncology Amarantus is paying $40,000, and the deal includes five patents and 20

January | February | March | April | May | June | July | August | September | October | November | December | December - 2012 Biotech Company Pharma Company Type/Product Area Terms/Details AIMM Therapeutics NV Cosmo Pharmaceuticals SpA Strategic partnership to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma Cosmo will formulate human monoclonal antibodies generated by AIMM in an extended-release form exploiting its MMX

marketing rights for uridine triacetate to treat accidental overexposure to chemotherapy drug fluorouracil due to dosing errors or imparied clearance from the body BTG gains rights in the U.S

marketing rights for uridine triacetate to treat accidental overexposure to chemotherapy drug fluorouracil due to dosing errors or imparied clearance from the body BTG gains rights in the U.S

When Spectrum out-licensed its bladder cancer treatment, apaziquone, to Allergan Inc., it retained co-marketing rights in the U.S

In addition, it has retained 50 percent co-promotion rights in the U.S

In addition, it has retained 50 percent co-promotion rights in the U.S

In addition, it has retained 50 percent co-promotion rights in the U.S

the agreement includes tiered double-digit royalties, and FivePrime retains minority co-promotion rights in the U.S

Alnylam also is eligible to receive significant milestones and royalties related to Takeda's successful advancement of RNAi therapeutic products, and has retained certain product opt-in rights in the U.S

In the new deal, HGS has acquired rights to develop and commercialize FP-1039 in the U.S., Canada and the European Union markets, while FivePrime retains minority co-promotion rights in the U.S

Aeterna Zentaris previously had out-licensed rights for the U.S., Canada and Mexico to Keryx Biopharmaceuticals Inc., of New York

January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Biotech Company Pharma Company Type/Product Area Terms/Details Akorn Inc. H. Lundbeck A/S Akorn's subsidiary, Oak Pharmaceuticals, acquired three off-patent, branded, hospital-based injectables Akorn will make an up-front payment of $45M and a subsequent milestone payment of $15M in cash after three years Amgen Inc. Watson Pharmaceuticals Inc. Deal to develop

January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Company Company Type/Product Area Terms/Details Ampio Pharmaceuticals Inc. Undisclosed party Deal to acquire rights to a patented orally disintegrating tablet drug delivery technology for use with Zertane, its candidate for premature ejaculation Financial terms were not disclosed AtheroNova Inc. OOO CardioNova (Russian subsidiary of Maxwell Biotech

XOMA has an option to reacquire diabetes and cardiovascular rights in the U.S...It also would have the freedom to license commercial rights in the U.S